Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people

Eleni Rapsomaniki, Adam Timmis, Julie George, Mar Pujades-Rodriguez, Anoop D Shah, Spiros Denaxas, Ian R White, Mark J Caulfield, John E Deanfield, Liam Smeeth, Bryan Williams, Aroon Hingorani, Harry Hemingway, Eleni Rapsomaniki, Adam Timmis, Julie George, Mar Pujades-Rodriguez, Anoop D Shah, Spiros Denaxas, Ian R White, Mark J Caulfield, John E Deanfield, Liam Smeeth, Bryan Williams, Aroon Hingorani, Harry Hemingway

Abstract

Background: The associations of blood pressure with the different manifestations of incident cardiovascular disease in a contemporary population have not been compared. In this study, we aimed to analyse the associations of blood pressure with 12 different presentations of cardiovascular disease.

Methods: We used linked electronic health records from 1997 to 2010 in the CALIBER (CArdiovascular research using LInked Bespoke studies and Electronic health Records) programme to assemble a cohort of 1·25 million patients, 30 years of age or older and initially free from cardiovascular disease, a fifth of whom received blood pressure-lowering treatments. We studied the heterogeneity in the age-specific associations of clinically measured blood pressure with 12 acute and chronic cardiovascular diseases, and estimated the lifetime risks (up to 95 years of age) and cardiovascular disease-free life-years lost adjusted for other risk factors at index ages 30, 60, and 80 years. This study is registered at ClinicalTrials.gov, number NCT01164371.

Findings: During 5·2 years median follow-up, we recorded 83,098 initial cardiovascular disease presentations. In each age group, the lowest risk for cardiovascular disease was in people with systolic blood pressure of 90-114 mm Hg and diastolic blood pressure of 60-74 mm Hg, with no evidence of a J-shaped increased risk at lower blood pressures. The effect of high blood pressure varied by cardiovascular disease endpoint, from strongly positive to no effect. Associations with high systolic blood pressure were strongest for intracerebral haemorrhage (hazard ratio 1·44 [95% CI 1·32-1·58]), subarachnoid haemorrhage (1·43 [1·25-1·63]), and stable angina (1·41 [1·36-1·46]), and weakest for abdominal aortic aneurysm (1·08 [1·00-1·17]). Compared with diastolic blood pressure, raised systolic blood pressure had a greater effect on angina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic blood pressure had a greater effect on abdominal aortic aneurysm than did raised systolic pressure. Pulse pressure associations were inverse for abdominal aortic aneurysm (HR per 10 mm Hg 0·91 [95% CI 0·86-0·98]) and strongest for peripheral arterial disease (1·23 [1·20-1·27]). People with hypertension (blood pressure ≥140/90 mm Hg or those receiving blood pressure-lowering drugs) had a lifetime risk of overall cardiovascular disease at 30 years of age of 63·3% (95% CI 62·9-63·8) compared with 46·1% (45·5-46·8) for those with normal blood pressure, and developed cardiovascular disease 5·0 years earlier (95% CI 4·8-5·2). Stable and unstable angina accounted for most (43%) of the cardiovascular disease-free years of life lost associated with hypertension from index age 30 years, whereas heart failure and stable angina accounted for the largest proportion (19% each) of years of life lost from index age 80 years.

Interpretation: The widely held assumptions that blood pressure has strong associations with the occurrence of all cardiovascular diseases across a wide age range, and that diastolic and systolic associations are concordant, are not supported by the findings of this high-resolution study. Despite modern treatments, the lifetime burden of hypertension is substantial. These findings emphasise the need for new blood pressure-lowering strategies, and will help to inform the design of randomised trials to assess them.

Funding: Medical Research Council, National Institute for Health Research, and Wellcome Trust.

Copyright © 2014 Rapsomaniki et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Forest plot of HRs (95% CIs) per 20/10 mm Hg increase in systolic (black) or diastolic (grey) blood pressure, adjusted for age and sex The vertical dashed lines correspond to the associations of SBP (black) or DBP (grey) with total cardiovascular disease. Adjustments include age, quadratic age, and stratification by sex and primary care practice. CIs are Bonferroni corrected (13 endpoints × 2 variables=26 tests). HR=hazard ratio. SBP=systolic blood pressure. DBP=diastolic blood pressure.
Figure 2
Figure 2
Forest plots of HRs (95% CIs) for 20/10 mm Hg changes in blood pressure in different age groups, adjusted for age and sex Models included continuous age, age group, interaction between blood pressure and age group (which is the association reported in the forest plot), and stratification by sex and primary care practice. CIs are Bonferroni corrected (3 age groups × 12 endpoints=36 tests). HR=hazard ratio.
Figure 3
Figure 3
Forest plots of HRs (95% CIs) for different cutoffs of systolic blood pressure (vs reference 115 mm Hg) adjusted for age and sex Blood pressure was modelled as a continuous variable with splines with three knots. Adjustments include age, quadratic age, and stratification by sex and primary care practice. CIs are Bonferroni corrected (3 age groups × 6 categories × 12 endpoints=216 tests). HR=hazard ratio.
Figure 4
Figure 4
Forest plot of HRs (95% CIs) for different cutoffs of diastolic blood pressure (vs reference 75 mm Hg) adjusted for age and sex Blood pressure was modelled as a continuous variable with splines with three knots. Adjustments include age, quadratic age, and stratification by sex and primary care practice. CIs are Bonferroni corrected (3 age groups × 6 categories × 12 endpoints=216 tests). HR=hazard ratio.
Figure 5
Figure 5
Lifetime risk (95% CI) of 12 different cardiovascular diseases in people with hypertension or normal BP from index age 30 years Hypertension was defined as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg or use of BP-lowering treatments or physician-recorded diagnosis at baseline. BP=blood pressure.
Figure 6
Figure 6
Years of life lost to cardiovascular disease up to 95 years of age associated with hypertension at index ages 30, 60, and 80 years, adjusted for sex, smoking, diabetes, and total and high-density lipoprotein cholesterol 83 098 total cardiovascular disease events occurred.

References

    1. Lim SS, Vos T, Flaxman AD. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260.
    1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, the Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
    1. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624.
    1. Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM. Lifetime risk and years lived free of total cardiovascular disease. JAMA. 2012;308:1795–1801.
    1. Lloyd-Jones DM, Leip EP, Larson MG, Vasan RS, Levy D. Novel approach to examining first cardiovascular events after hypertension onset. Hypertension. 2005;45:39–45.
    1. Denaxas SC, George J, Herrett E. Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER) Int J Epidemiol. 2012;41:1625–1638.
    1. Herrett E, Shah AD, Boggon R. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ. 2013;346:f2350.
    1. Gallagher AM, Puri S, van Staa TP. Linkage of the General Practice Research Database (GPRD) with other data sources. Pharmacoepidemiol Drug Saf. 2011;20:S230–S367.
    1. Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997;350:1097–1099.
    1. Rubin DB. Multiple imputation for nonresponse in surveys. John Wiley and Sons; New York: 1987.
    1. Go AS, Mozaffarian D, Roger VL, the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–245.
    1. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172:137–159.
    1. Cadarso-Suarez C, Meira-Machado L, Kneib T, Gude F. Flexible hazard ratio curves for continuous predictors in multi-state models: a P-spline approach. Stat Model. 2010;10:291–314.
    1. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd edn. John Wiley and Sons; New York: 2002.
    1. Andersen PK. Decomposition of number of life years lost according to causes of death. Stat Med. 2013;32:5278–5285.
    1. Social Exclusion Task Force . Improving the way we meet the primary health care needs of the socially excluded. Joint Health Surveys Unit. The Cabinet Office; Leeds: 2010.
    1. Kannel WB, Wilson PW, Nam BH, D'Agostino RB, Li J. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol. 2004;94:380–384.
    1. Beckett N, Peters R, Tuomilehto J, the HYVET Study Group Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to hypertension in the very elderly randomised controlled trial. BMJ. 2012;344:d7541.
    1. Lloyd-Jones DM, Larson MG, Leip EP, the Framingham Heart Study Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–3072.
    1. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961–965.
    1. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 2007;6:1106–1114.
    1. Vlak MH, Rinkel GJ, Greebe P, Greving JP, Algra A. Lifetime risks for aneurysmal subarachnoid haemorrhage: multivariable risk stratification. J Neurol Neurosurg Psychiatry. 2013;84:619–623.
    1. Berry JD, Dyer A, Cai X. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321–329.
    1. Wills AK, Lawlor DA, Muniz-Terrera G, the FALCon Study Team Population heterogeneity in trajectories of midlife blood pressure. Epidemiology. 2012;23:203–211.
    1. National Clinical Guideline Centre Hypertension: clinical management of primary hypertension in adults. NICE Clinical Guideline 127. August, 2011. (accessed Nov 4, 2013).
    1. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;8 CD006742.
    1. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371:2219–2221.
    1. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromsø Study, 1994–2001. Circulation. 2009;119:2202–2208.
    1. Franks PJ, Edwards RJ, Greenhalgh RM, Powell JT. Risk factors for abdominal aortic aneurysms in smokers. Eur J Vasc Endovasc Surg. 1996;11:487–492.
    1. Goff DC, Jr, Lloyd-Jones DM, Bennett G. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013 published online Nov 12.
    1. JBS3 Board Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart. 2014;100(suppl 2):ii1–i67.
    1. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimäki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA. 2006;295:1404–1411.
    1. Hirsch AT, Duval S. The global pandemic of peripheral artery disease. Lancet. 2013;382:1312–1314.
    1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110:738–743.
    1. Turnbull F, the Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535.
    1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

Source: PubMed

3
Abonneren